Songling Xuemaikang Capsule for primary hypertension with the control of Losartan potassium: a multi-center, randomized, double-blind controlled trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-16008108

Enrollment

Unknown

Registered

2016-03-16

Start date

2015-12-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension

Interventions

treatment group:Songling Xuemaikang capsule,the placebo of Losartan Potassium

positive control group:Losartan Potassium, the placebo of Songling Xuemaikang capsule

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosed with primary hypertension, having mean systolic blood pressure >=140 mmHg and =90mmHg and <100 mmHg without antihypertensive therapy; 2. Diagnosed of liver yang hyperactivity syndrome; 3. Without antihypertensive therapy; 4. Aged between 18-65 years old, both male and female; 5. Signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Unstable angina, cerebrovascular accident, myocardial infarction or heart failure disease; 2. Definite or suspected secondary hypertension; 3. Type 1 diabetes mellitus, type 2 diabetes mellitus with poor blood glucose control (fasting blood glucose>11mmol/L), or T2DM with complications (nephrosis, peripheral neuropathy); 4. Gastroenteropathy, or gastrointestinal surgery possibly influencing drug absorption; 5. Combined with some other cardiovascular, cerebrovascular, liver, kidney, hematopoietic system and other serious primary diseases or malignancy (include unilateral or bilateral renal artery stenosis); 6. Allergic constitution; 7. Pregnancy or lactation women or recent pregnancy preparation; 8. History of alcohol and substance abuse, with other diseases and special conditions that complicating the enrollment or reducing the possibility of subjects selected, such as job changes frequently to loss to follow-up.

Design outcomes

Secondary

Measure	Time frame
SeSBP;Rate of BP;Quality of Life assessment;Hypertension symptom score;Headache symptom score;ABPM;TCM symptom score;	—

Primary

Measure	Time frame
SeDBP;	—

Countries

China

Contacts

Public ContactGao Ying

Dongzhimen Hospital affiliated to Beijing University of Chinese Medicine

gaoying973@126.com+86 010-84013209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 13, 2026